You are currently viewing Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

In this Issue

  • The Psychedelics Circuit: Dispatches from Prague and London, Looking Ahead to Denver
    • EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle
    • At ‘the Davos of Mental Health’, Investors Eye Psychedelics’ Next Chapter
    • Join Us in Denver: Psychedelic Alpha at Psychedelic Science 2025
  • High-Dose LSD Shows Potential in Depression Trial, But Findings Are Fragile
  • Lone Star State Becomes Leader in Ibogaine Research
  • One-Year Outcomes from Psilocybin Study in Veterans with TRD
  • A Series of Unfortunate Events: Recent Incidents Underscore Psychedelic Safety
  • and more…

***

The Psychedelics Circuit: Dispatches from Prague and London, Looking Ahead to Denver

Earlier this week, I participated in conferences in Prague and London, and on Sunday I travel to Denver for Psychedelic Science 2025. Below, I share my notes from the two European meetings, plus a brief look ahead to Denver.

– Josh Hardman, Founder & Editor

EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle

On Monday, I had the privilege of participating in a conference at Prague Castle in the Czech Republic titled Novel Mental Health Treatments: Czechia as a Leader of the EU? The subtitle, meanwhile, was Increasing Societal Resilience and Coping with War Trauma.

The meeting, organised by PsychedelicsEUROPE and Czech nonprofit PSYRES, attracted policymakers, researchers, advocates, and others to discuss Czechia’s potential to lead the EU in terms of novel mental health treatments. It came just a week or so after it became clear that the Czech Parliament looks set to legalise the medical use of psilocybin.

Much of the morning’s discussion focused on the war in Ukraine and how the Czech Republic might provide support to those suffering from mental health disorders as a result. We heard from representatives from groups like NATO, the Czech Armed Forces, Czech MPs, Ukraine’s Deputy Minister of Health Edem Adamanov, Oksana Gryshchenko of Heal Ukraine Trauma, and others.

Czech Governmental Envoy for the Reconstruction of Ukraine Tomáš Kopečný said that he visited the Superhumans Center in Vynnyky, a rehabilitation clinic for those who have lost limbs or had other life-altering injuries since the 2022 Russian invasion and war. But now, he says, we must also focus on mending the minds of those victims.

While the country has ambitions to help Ukraine, diplomat Petr Kolář—who has served as Czech ambassador to both Russia and the U.S.—urged attendees to be attentive to the need for Czechia to build resilient mental health internally, too. ‘You must apply your own oxygen mask first’, he said.

Later in the day, Oksana Gryshchenko of Heal Ukraine Trauma said that supporting innovative mental health in Ukraine isn’t necessarily a one-way street, but instead offers opportunities for bi-directional learnings. In her experience, when experts from around the world have visited Ukraine and spoken to local therapists about their patients, “their eyes pop up”, she told the audience, adding that they often learn about new ways of delivering therapies that have helped Ukrainians.

She also reminded the audience that a prerequisite for any psychedelic research and practice in Ukraine is modifying the country’s controlled substances statute, which remains under deliberation.

Speaking on the same panel, Ukraine’s Deputy Minister of Health Edem Adamanov emphasised that his ministry can do two important things when it comes to novel mental health interventions: ‘make them accessible and allocate resources.’ He shared an example of how his team set out to improve primary care doctors’ understanding of mental health, to improve referrals and so on.

Again emphasising the importance of scalability and affordability when discussing mental health treatments, Adamanov told the audience that it is very important for such therapies to be supported in the long term. ‘If you implement something one year and not the next, it’s very difficult.’ Gryshchenko agreed on the scalability front, suggesting that we look at group therapy in the context of psychedelics, for example.

But Adamanov also shared how, during war, getting the basics right is equally important: ‘sleep well when you can, eat well, and love your loved ones.’ He told the predominantly Czech crowd that it is wise to invest in promising new therapies when you’re not under full-scale invasion…

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…

Join Pα+ Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.


Already a member? Log In


   Regular Bulletins covering key topics and trends in the psychedelics space
   Regular articles and deep dives across psychedelic research, policy and business
   Interviews with insiders
   Monthly interactive database and commentary on psychedelic patents
   Quick-take analysis of major developments
   A Library of primers and explainers
   Access to our full back catalogue


Learn more about Pα+